FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 8, 2021

NEURONETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware  001-38546  33-1051425
(State or other jurisdiction  (Commission  (I.R.S. Employer
of incorporation)  File Number)  Identification No.)

3222 Phoenixville Pike, Malvern, PA  19355
(Address of principal executive offices)  

Registrant’s telephone number, including area code (610) 640-4202

(Former name or former address, if changed since last report.) Not applicable.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class  Trading Symbol (s)  Name on each exchange on which registered

Common Stock ($0.01 par value)  STIM  The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
(b) On March 8, 2021, Gregory Harper, the Vice President R&D and Clinical of Neuronetics, Inc. (the “Company”) notified the Company of his intent to retire effective March 31, 2021. To assist in the transition of his responsibilities, Mr. Harper and the Company intend to enter into a three month consulting agreement under which Mr. Harper will be compensated at the rate of $200 per hour, plus reimbursement of expenses.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEURONETICS, INC.
(Registrant)

Date: March 11, 2021

By:  /s/ Stephen Furlong
Name:  Stephen Furlong
Title:  SVP, Chief Financial Officer and Treasurer
       (Principal Financial and Accounting Officer)